Denmark-based healthcare company Novo Nordisk plans to invest $4.1 billion to expand its manufacturing capacity in the United States with a second filling and finishing facility in Clayton, North Carolina.
With 1.4 million square feet of production space for aseptic manufacturing and finished production processes, the facility would double the combined footprint of Novo Nordisk’s three existing plants in North Carolina. The new facility would include more than 10 buildings constructed on a 56-acre site near two other Novo Nordisk facilities in Clayton. The most recent was completed in 2020. The company’s other North Carolina facility is located in Durham.
“Clayton was Novo Nordisk’s first U.S. manufacturing site, and this new large-scale investment here confirms the continued importance of our production facilities in North Carolina,” said Niels Laurbjerg Nielsen, corporate vice president of Novo Nordisk, in a statement.
BE&K Building Group, Morrisville, North Carolina, is directly performing much of the work as the project’s construction manager and will serve as the agency’s construction manager for the remainder. The first site and foundation work is currently being carried out.
Novo Nordisk has set itself the goal of achieving LEED Gold certification. It plans to include rooftop solar panels and “innovative water strategies” to make the facility environmentally efficient.
The project is scheduled to be phased out between 2027 and 2029.
Novo Nordisk says it plans to produce injectable treatments for obesity and chronic diseases at the plant.
